 BEVERLY HILLS, Calif., Sept. 13, 2021 PRNewswire -- GT Biopharma, Inc. the Company NASDAQ: GTBP, a clinical stage immuno-oncology company focused on developing innovative therapeutics based on the Companys proprietary natural killer NK cell engager, TriKE protein biologic technology platform, today, announces the advancement of GTB-3650 into IND-enabling studies, with which it plans to supplant the ongoing Phase 1 program with GTB-3550. 